QLP2117

N/A

Report date: 2026/02/26 20:00:22

Base Information

Drug NameQLP2117
Drug Alias NameQLP2117QLP-2117
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionC-C chemokine receptor type 8 modulators
TargetsC-C chemokine receptor type 8
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesQilu Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A